Stockreport

PHASE 3 STUDY OF NOVEL ANTI-PLATELET DRUG FOR HEART ATTACK REPORTS POSITIVE TOPLINE RESULTS [Yahoo! Finance]

ITOCHU CORP UNSP/ADR  (ITOCY) 
NASDAQ:AMEX Investor Relations: itochu.co.jp/en/ir/index.html
PDF Disaggpro™ (zalunfiban) has shown positive primary efficacy and primary safety outcomes. The full results from the CeleBrate study will be released on Nov. 10 as part of [Read more]